File:Are tyrosine kinase inhibitors promising for the treatment of systemic sclerosis and other fibrotic diseases?.pdf
Jump to navigation
Jump to search
Link to the index page
Size of this JPG preview of this PDF file: 423 × 599 pixels. Other resolutions: 169 × 240 pixels | 339 × 480 pixels | 542 × 768 pixels | 1,239 × 1,754 pixels.
Original file (1,239 × 1,754 pixels, file size: 306 KB, MIME type: application/pdf, 5 pages)
 | This is a file from the Wikimedia Commons. Information from its description page there is shown below. Commons is a freely licensed media file repository. You can help. |
Summary
| Description |
English: Tissue fibrosis causes organ failure and death in patients with systemic sclerosis (SSc), but clearly effective anti-fibrotic therapies are not available. The tyrosine kinase inhibitor (TKI) imatinib, which blocks the pro-fibrotic c-Abl kinase and PDGF receptor, is currently evaluated in clinical proof-of-concept trials for the treatment of patients with SSc. In experimental models, imatinib efficiently prevented and reduced tissue fibrosis. First clinical case studies demonstrated anti-fibrotic effects of imatinib in selected patients with SSc and other fibrotic diseases, and observational studies in sclerotic chronic graft-versus-host disease showed promising results. Besides imatinib, the two novel TKIs of c-Abl and PDGF receptor nilotinib and dasatinib have recently proven efficacy in experimental models of SSc. The potential of TKIs of the VEGF receptor (e.g., semaxinib, vatalanib, sutent, and sorafenib) and the EGF receptor (e.g., erlotinib, gefitinib, lapatinib, and canertinib) as anti-fibrotic treatments are also discussed in this review. Prior to clinical use, however, controlled trials need to address efficacy as well as tolerability of TKIs in patients with different fibrotic diseases. |
| Date | |
| Source | https://smw.ch/index.php/smw/article/view/1177/1238 |
| Author | Christian Beyer, Jörg H. W. Distler, Oliver Distler |
Licensing
This file is licensed under the Creative Commons Attribution-Share Alike 4.0 International license.
- You are free:
- to share – to copy, distribute and transmit the work
- to remix – to adapt the work
- Under the following conditions:
- attribution – You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- share alike – If you remix, transform, or build upon the material, you must distribute your contributions under the same or compatible license as the original.
File history
Click on a date/time to view the file as it appeared at that time.
| Date/Time | Thumbnail | Dimensions | User | Comment | |
|---|---|---|---|---|---|
| current | 20:01, 14 July 2023 |  | 1,239 × 1,754, 5 pages (306 KB) | VGPaleontologist | Uploaded a work by Christian Beyer, Jörg H. W. Distler, Oliver Distler from https://smw.ch/index.php/smw/article/view/1177/1238 with UploadWizard |
File usage
The following page uses this file:
Global file usage
The following other wikis use this file:
- Usage on www.wikidata.org